907 related articles for article (PubMed ID: 25300866)
1. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
2. [Clinical observation of mesenchymal stem cell as salvage treatment for refractory acute graft-versus-host disease].
Zhao K; Huang F; Peng YW; Zhou HS; Fan ZP; Zhang X; Guo XT; Xu N; Sun J; Xiang P; Liu QF
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):122-6. PubMed ID: 23611218
[TBL] [Abstract][Full Text] [Related]
3. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study.
Liu X; Wu M; Peng Y; Chen X; Sun J; Huang F; Fan Z; Zhou H; Wu X; Yu G; Zhang X; Li Y; Xiao Y; Song C; Xiang AP; Liu Q
Cell Transplant; 2014; 23(9):1087-98. PubMed ID: 23294601
[TBL] [Abstract][Full Text] [Related]
4. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
[TBL] [Abstract][Full Text] [Related]
5. [Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease].
Zhang LS; Liu QF; Huang K; Zhang Y; Fan ZP; Huang SL
Zhonghua Nei Ke Za Zhi; 2009 Jul; 48(7):542-6. PubMed ID: 19957792
[TBL] [Abstract][Full Text] [Related]
6. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation.
Jitschin R; Mougiakakos D; Von Bahr L; Völkl S; Moll G; Ringden O; Kiessling R; Linder S; Le Blanc K
Stem Cells; 2013 Aug; 31(8):1715-25. PubMed ID: 23554294
[TBL] [Abstract][Full Text] [Related]
8. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.
Pastore D; Delia M; Mestice A; Carluccio P; Perrone T; Gaudio F; Curci P; Rossi AR; Ricco A; Specchia G
Biol Blood Marrow Transplant; 2012 Jun; 18(6):887-93. PubMed ID: 22062803
[TBL] [Abstract][Full Text] [Related]
9. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
[TBL] [Abstract][Full Text] [Related]
10. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy.
von Bahr L; Sundberg B; Lönnies L; Sander B; Karbach H; Hägglund H; Ljungman P; Gustafsson B; Karlsson H; Le Blanc K; Ringdén O
Biol Blood Marrow Transplant; 2012 Apr; 18(4):557-64. PubMed ID: 21820393
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.
Jang MJ; Kim HS; Lee HG; Kim GJ; Jeon HG; Shin HS; Chang SK; Hur GH; Chong SY; Oh D; Chung HM
Acta Haematol; 2013; 129(4):197-206. PubMed ID: 23257958
[TBL] [Abstract][Full Text] [Related]
13. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
15. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.
Ball LM; Bernardo ME; Roelofs H; van Tol MJ; Contoli B; Zwaginga JJ; Avanzini MA; Conforti A; Bertaina A; Giorgiani G; Jol-van der Zijde CM; Zecca M; Le Blanc K; Frassoni F; Egeler RM; Fibbe WE; Lankester AC; Locatelli F
Br J Haematol; 2013 Nov; 163(4):501-9. PubMed ID: 23992039
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
Le Blanc K; Frassoni F; Ball L; Locatelli F; Roelofs H; Lewis I; Lanino E; Sundberg B; Bernardo ME; Remberger M; Dini G; Egeler RM; Bacigalupo A; Fibbe W; Ringdén O;
Lancet; 2008 May; 371(9624):1579-86. PubMed ID: 18468541
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
[TBL] [Abstract][Full Text] [Related]
19. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium.
von Bonin M; Stölzel F; Goedecke A; Richter K; Wuschek N; Hölig K; Platzbecker U; Illmer T; Schaich M; Schetelig J; Kiani A; Ordemann R; Ehninger G; Schmitz M; Bornhäuser M
Bone Marrow Transplant; 2009 Feb; 43(3):245-51. PubMed ID: 18820709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
